Rituximab In Combination With Sargramostim (GM-CSF) In Patients With Chronic Lymphocytic Leukemia (CLL).
Phase of Trial: Phase II
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Sargramostim (Primary) ; Rituximab
- Indications Chronic lymphocytic leukaemia
- Focus Therapeutic Use
- 15 Feb 2017 Status changed from active, no longer recruiting to completed.
- 02 Feb 2017 Planned primary completion date changed from 1 Aug 2017 to 1 Aug 2018.
- 02 Feb 2016 Planned primary completion date changed from 1 Aug 2016 to 1 Aug 2017 as reported by ClinicalTrials.gov record.